Suzhou Dixinchenke Biotechnology

Suzhou Dixinchenke Biotechnology is a Chinese biopharmaceutical company focused on the discovery and development of innovative small molecule immunotherapies. The company specializes in targeting the innate immune system, particularly through the development of Toll-like receptor (TLR) agonists for the treatment of cancer and chronic infectious diseases. Their research emphasizes the creation of highly selective TLR7 and TLR8 modulators designed to enhance anti-tumor immune responses while minimizing systemic toxicity. Based in the Suzhou Industrial Park, the firm leverages its proprietary drug discovery platform to advance a pipeline of candidates through early-stage development.